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Because it has been suggested that the majority of the
activity hydrolysing [N-methyl-14C] sphingomyelin is due
to sphingomyelin acylase in the lesional skins of atopic
dermatitis (AD), in this study we used immunologic
techniques to localize and quantitate sphingomyelinase
in AD lesional and normal skin. A polyclonal antibody
raised against a synthetic polypeptide corresponding to
a portion of the amino acid sequence deduced from the
cDNA of human acid sphingomyelinase, cross-reacted
with a 58 kDa, pI 5.8 human epidermal protein in an
immunoblot analysis. The 58 kDa protein-rich fraction,
partially purified by immunoprecipitation, converted
[N-methyl-14C]-sphingomyelin to 14C-phosphorylcho-
line and ceramides. The reaction products were immuno-
histochemically observed in the intercellular domain from
the upper spinous cell layer to the upper stratum corneum
The intercellular lipids of the stratum corneum constitutethe epidermal permeability barrier (Elias and Friend,1975; Wertz and Downing, 1982) and around 50% ofthese intercellular lipids are ceramides (Wertz et al, 1985;Ranasinghe et al, 1986). As ceramides are an important
determinant of water-holding properties (Imokawa and Hattori, 1985;
Imokawa et al, 1986, 1991b) and stratum corneum barrier function
(Lampe et al, 1983; Grubauer et al, 1989; Holleran et al, 1991a;
Imokawa et al, 1994), the insufficiency of ceramides in the stratum
corneum may be the cause of such barrier-disrupted skin as atopic dry
skin. In normal skin, ceramides are produced in the stratum corneum by
degradation of glucosylceramides by beta-glucocerebrosidase (Holleran
et al, 1992, 1993) and by hydrolysis of sphingomyelin by sphingo-
myelinase (SMase) (Menon et al, 1986; Yamamura and Tezuka, 1990),
whereas the production of glucosylceramides and sphingomyelin is
catalyzed by serine palmitoyltransferase in the spinous-granular cell
layers (Holleran et al, 1991a, b). The main pathway of ceramide synthesis
in human epidermis is thought to be the one from glucosylceramides to
ceramides. In contrast, in the tape-stripped stratum corneum of atopic
dermatitis (AD) patients, the hydrolytic degradation of [N-methyl-
14C]sphingomyelin is enhanced by more than 25-fold in involved skin
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cell layers in the lesional skin of AD patients. Immuno-
electron-microscopically, gold particles appeared to be
concentrated in the intercellular domains of the granular-
upper stratum corneum cells in the lesional skin of AD
patients. The total amount of the 58 kDa protein in a 7
mm2 area of the skin was measured by quantitative
immunoblot analysis; and was slightly increased in the
lesional skin samples [3.5 K 0.3 mg per 7 mm2 (n J 7)],
as compared with the nonlesional skin samples of AD
patients [2.8 K 0.19 mg per 7 mm2 (n J 10)] and with
the normal skin samples [2.7 K 0.22 mg per 7 mm2
(n J 10)]. This difference (between the lesional skin of
AD and the nonlesional skin of AD or the normal control)
was significant (nonpaired student’s t test, p < 0.05). Key
words: atopic dermatitis/ceramides/epidermal localization of
SMase. J Invest Dermatol 111:733–738, 1998
and by more than 6- to 11-fold in uninvolved skin, and the hydrolytic
activity is highest in the lower stratum corneum. Most of the enhanced
hydrolytic activity was attributed not to SMase but to sphingomyelin
acylase (SM acylase) (Murata et al, 1996). Therefore, in the AD
patients’ epidermis, an altered metabolic pathway of sphingomyelin
was suggested (Murata et al, 1996): large amounts of sphingosylphos-
phorylcholine and free fatty acids are formed, but the amounts of
ceramides are decreased. This indicates that the activity of SMase
cannot be measured simply by measuring the hydrolytic degradation
of [N-methyl-14C]sphingomyelin.
Mammalian SMases have recently been implicated in many important
physiologic and pathologic processes: (i) ceramide-mediated signal
transduction, leading to cytokine-induced apoptosis, cellular differ-
entiation, and various immune and inflammatory responses (Obeid
et al, 1993; Cifone et al, 1994; Tepper et al, 1995); (ii) lipoprotein
aggregation within vessel walls; and (iii) intracellular cholesterol
trafficking and metabolism (Kolesnick, 1991). Several different forms
of mammalian SMase have been identified, including (i) a lysosomal
SMase, (ii) a neutral, membrane-associated SMase, (iii) a cytosolic
SMase, and (iv) an acidic, Zn21-stimulated SMase (Schissel et al, 1996).
In normal mammalian epidermis, SMase was histochemically shown
to be located in the cytoplasm of the stratum granulosum cells of the
neonatal mouse epidermis (Elias et al, 1979), and was biochemically
shown to be contained in the lamellar granule-rich fraction from the
epidermal homogenate of fetal rat skin (Freinkel and Traczyk, 1985).
In human skin, SMase activity was found to be decreased in aged, dry
skin (Yamamura and Tezuka, 1990), but the amount of SMase was the
same in nonlesional skin of AD and normal control skins (Cui et al,
1997); however, the amount of SMase and ultrastructural localization
of SMase in lesional skins of AD patients has not been reported.
The purpose of this study was to examine the ultrastructural
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localization of human epidermal SMase, and to measure its amount
in the lesional skin of AD patients by quantitative immunoblot
analysis (QIA).
MATERIALS AND METHODS
Polyclonal antibody production As recombinant SMase was not available
in Japan when this project was started, and because measuring and comparing
the amount of SMase by QIA was the one of the aims of this study, a
polypeptide corresponding to a portion of the amino acid sequence deduced
from the cDNA of human acid SMase (Quintern et al, 1989) was synthesized
using a peptide synthesizer (Shimadzu, Kyoto, Japan), and used to produce an
anti-serum in rabbits. The synthetic polypeptide was G-E-L-Q-A-A-E-D-R-
G-D-K, which corresponds to amino acids 408–419 in the amino acid sequence
of human acid SMase, and is relatively strong in antigenicity (Hopp and Woods,
1981). In addition, cysteine was bound to the terminal lysine in order to bind
this synthetic polypeptide with keyhole limpet hemocyanin (Calbiochem-
Novabiochem, La Jolla, CA). To immunize a rabbit, 0.6 mg of synthetic
polypeptide bound to keyhole limpet hemocyanin was used, together with
complete Freund’s adjuvant. Two weeks after the initial immunization, boosting
was done by injecting 0.6 mg of synthetic polypeptide bound to keyhole limpet
hemocyanin. The boosting was repeated until a high titer of antibody [anti-
sphingomyelinase antibody (anti-SM Ab)], which cross-reacted with human
epidermis, was obtained.
Enzyme-linked immunosorbent assay To determine whether or not
the antibody reacted with the synthetic polypeptide itself, enzyme-linked
immunosorbent assay was performed by the technique of Voller et al (1978).
An unrelated synthetic peptide and preimmune serum were used as the controls.
Immunoblot examination Defatted skin obtained by a punch biopsy was
immediately lyophilized, minced, homogenized in 50 mM Tris-HCl buffer,
pH 7.2, containing 1% sodium dodecylsulfate (SDS) in a conical glass homo-
genizer and centrifuged at 15,000 3 g for 30 min. The 15,000 3 g supernatant
fraction was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to Immobilon (Millipore, Bedford, MA), and allowed to react with
anti-SM Ab diluted 1:1000. To compare the amount of epidermal SMase in
the nonlesional (currently no dermatitis) and lesional (lichenification) skins of
AD patients and in the skin of one of the age-matched normal controls, punch-
biopsied skin samples (3 mm in diameter) were obtained from the inner surface
of the upper arm of normal persons and AD patients (nonlesional skin), and
from forehead, cheek, neck, and breast as the lesional skins of AD patients.
Samples from forehead were used for both immunohistochemical and QIA
studies, and samples from cheek, neck, and breast were used only for QIA
measurements of the amount of epidermal SMase protein.
For two-dimensional electrophoresis, an extract of suction blister epidermis
from normal persons in 100 mM Tris-HCl buffer, pH 9.2, containing 10 M
urea was subjected first to isoelectric focusing electrophoresis, using a capillary,
and then to SDS-PAGE, and transferred onto Immobilon and allowed to react
with 1:1000 diluted anti-serum. The reaction products on Immobilon were
further allowed to react with anti-rabbit IgG goat IgG labeled with peroxidase
(1:1000 dilution). Cross-reactivity of this anti-SM Ab with human placental
SMase (Sigma, St Louis, MO) was also examined.
SMase activity of the 58 kDa epidermal protein fraction obtained by
immunoprecipitation The 58 kDa protein was collected by immuno-
precipitation (Hurwitz et al, 1994). Briefly, 50 mg of normal epidermis (dry
weight) obtained from suction blisters was homogenized in 1.0 ml of 100 mM
Tris-HCl buffer, pH 8.0, containing 8 M urea, 0.334 TIU aprotinin per ml
and 1 mg PMSF per ml. After centrifugation at 18,500 3 g for 15 min, the
resultant supernatants were diluted with 10 volumes of 100 mM Tris-HCl
buffer, pH 8.0, and chilled in ice water for 15 min during which the precipitation
occurred. After the precipitate was pelleted by centrifugation at 18,500 3 g for
15 min, the pellet was dissolved in 50 mM Tris-HCl buffer, pH 7.2, containing
0.5% SDS, and again centrifuged at 18,500 3 g for 15 min. The supernatant
was diluted 10-fold with 50 mM Tris-HCl buffer, pH 7.2. One milliliter of
this diluted supernatant fraction (SF) was incubated with 10 µl of either anti-
SM Ab or preimmune serum and 10 mg of protein A-Sepharose (PAS) at 4°C
for 16 h. Then, after centrifugation at 18,500 3 g for 15 min, the pellet was
washed three times in 50 mM Tris-HCl buffer, pH 7.2, and finally dissolved
in 250 µl of 50 mM acetate buffer, pH 4.7, containing 20 mM calcium
chloride and 0.1% Triton X-100. This solution was used to determine SMase
activity, according to the method of Bowser and Gray (1978). The final
incubation mixture (0.5 ml) contained 1 µ Ci[N-methyl-14C]-sphingomyelin,
Triton X-100 (0.1%, vol/vol), calcium chloride (20 mM), and 0.25 ml of the
sample fractions in 50 mM acetate buffer, pH 4.7. Incubation was carried out
for 90 min at 37°C, after which the reaction was stopped by the addition of
0.5 ml of water and 2 ml of chloroform:methanol (2:1, vol/vol). The aqueous
upper layer was removed and added to 10 ml of PCS liquid scintillator/
solubilizer. The radioactivity in the water-soluble fraction was measured
with a liquid scintillation spectrometer. Results were expressed as dpm of
[14C]phosphorylcholine formed per min after the value of the control was sub-
tracted.
The neutralization/elimination of SMase activity by this antibody in vitro was
not tested, as it was not certain that the amino acid sequence selected for
antibody production in this study was identical to the amino acid sequence of
the active site of the epidermal SMase. Instead, the epidermal SMase was
collected by immunoprecipitation and its activity was determined.
Immunohistochemistry The labeled streptavidin biotin method (Guesdon
et al, 1979) was used to detect the antigen site in the epidermis. Four-micron
frozen skin sections that were fixed in 95% cold ethanol (–20°C) for 10 min
were reacted with anti-SM Ab diluted 1:2000 or preimmune serum diluted
1:2000 at 37°C for 30 min.
Immunoelectron microscopy Either normal human forearm skin that was
obtained from a surgical operation for a benign skin tumor or the lesional skin
of AD patients was minced into 1 mm cubes and immediately fixed in 2.5%
glutaraldehyde and 4% paraformaldehyde in 50 mM phosphate buffer, pH 7.2,
at 4°C for 1 h, and then rinsed thoroughly in 50 mM phosphate buffer and
embedded in Unicryl resin. Thin sections were prepared from the thus-
embedded skin specimens and were reacted first with either anti-SM Ab diluted
1:1000 or preimmune serum diluted 1:1000 at 4°C overnight, and then with
an anti-rabbit IgG goat IgG labeled with 15 nm gold particles (1:150 in dilution)
at 37°C for 30 min. These sections were then stained with uranyl acetate and
lead nitrate, and examined under an electron microscope.
The amount of the 58 kDa protein in skin of AD patients, determined
by QIA Punch-biopsied skin, 3 mm in diameter, was obtained from the
inner-surface skin of the upper arm of both 10 AD patients (the nonlesional
skin) and 10 age-matched normal controls, and from the lesional skins (forehead,
cheek, neck, and breast) of seven AD patients. The specimens were immediately
frozen in liquid nitrogen, lyophilized, and stored at –80°C until use. Consent
was obtained before biopsy.
The amount of the 58 kDa protein reacting with anti-SM Ab in these
punch-biopsied skins was estimated using QIA, a previously reported method
(Seguchi et al, 1996; Cui et al, 1997). Briefly, the lyophilized skins were minced
and homogenized in 50 mM Tris-HCl buffer, pH 7.2, containing 1% SDS, in
a conical glass homogenizer, and centrifuged at 15,000 3 g for 10 min. An
aliquot of the supernatant fraction was subjected to SDS-PAGE, blotted onto
Immobilon, and allowed to react with either anti-SM Ab diluted 1:1000 or
preimmune serum diluted 1:1000. The reaction product was further allowed
to react with anti-rabbit IgG goat IgG labeled with peroxidase and diluted
1:1000, and the density of the protein band of 58 kDa was measured. The
amount of the 58 kDa protein was estimated from the standard curve of density
versus protein concentration produced using cystatin A (also called Stefin A) as
a standard for epidermal SMase, because purified SMase was not commercially
available. Aliquots of cystatin A (0.1–0.6 µg) were subjected to SDS-PAGE,
blotted onto Immobilon, and allowed to react with anti-cystatin A antibody,
diluted 1:1000. After peroxidase was visualized with hydrogen peroxide and
diaminobenzidine, the density of stained cystatin A was determined using a
chromato-scanning meter with a 10 mm 3 0.5 mm slit.
RESULTS
Enzyme-linked immunosorbent assay examination showed that
an antibody against the synthetic polypeptide of SMase was
produced The serum from the immunized rabbit reacted with the
synthetic polypeptide of SMase, but not with an unrelated synthetic
peptide, and the preimmune serum did not react with the synthetic
polypeptide of SMase (data not shown).
The antibody cross-reacted with a 58 kDa, pI 5.8 epidermal
protein and a 70 kDa human placental SMase protein in
immunoblot analysis When the Tris-SDS extract of the punch-
biopsied skin was separated by SDS-PAGE, blotted onto Immobilon,
and reacted with anti-SM Ab, a single, 58 kDa protein band was
detected (Fig 1A, lane 2, indicated by an arrowhead). The antibody was
also cross-reacted with a 70 kDa human placental SMase protein
(Fig 1B, lane 2).
Two-dimensional electrophoresis of the extracts from epidermis
revealed a single, 58 kDa immunoreactive spot at pI 5.8 (Fig 2a, b,
indicated by an arrow).
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Figure 1. Anti-SM Ab cross-reacts with a single 58 kDa epidermal
protein and a 70 kDa human placental SMase. (A) The extracts of
normal epidermis obtained from suction blisters were separated by SDS-PAGE,
transferred onto Immobilon, and reacted with preimmune serum (lane 1) or
with anti-SM Ab (lane 2). The proteins extracted from the epidermis were
stained with Coomassie brilliant blue R (lane 3). Lane 4 shows the following
molecular weight markers (from the top): bovine serum albumin (67 kDa),
ovalbumin (43 kDa), carbonic anhydrase (30 kDa), soybean trypsin inhibitor
(20.1 kDa), and lactalbumin (14.4 kDa). (B) The commercially available human
placental SMase was separated by SDS and transferred onto Immobilon and
reacted with preimmune serum (lane 1) or with anti-SM Ab (lane 2), and
stained with Coomassie brilliant blue R (lane 3). Lane 4 shows the molecular
weight markers.
Figure 2. A single spot reacts with anti-SM Ab in two-dimensional
immunoblotting analysis of epidermal extracts. (a) Immunoblot; (b)
Coomassie blue stains.
The 58 kDa protein fraction obtained by immunoprecipitation
hydrolyzed [N-methyl-14C] sphingomyelin The presence of the
58 kDa protein in various fractions was examined by immunoblotting.
The protein was present in a partially purified supernatant fraction (SF)
obtained as described in Materials and Methods. SF was used for
immunoprecipitation, and the 58 kDa protein was solubilized with
0.16 M acetic acid from the pellet of the immunoprecipitation reaction
with anti-SM Ab, as shown in Fig 3, lane 4. No 58 kDa protein,
however, was found in the solubilized fraction from the pellet of the
immunoprecipitation reaction with preimmune serum (Fig 3, lane 5).
The ability to hydrolyze [N-methyl-14C] sphingomyelin was
examined in the pellets after centrifugation of the immunoprecipitation
reactions [either SF, anti-SM-Ab and PAS, or SF, preimmune serum
and PAS (the control)]. The SMase activities of seven of these pellets
after the background activity of the control was subtracted are shown
in Table I. The hydrolytic activity of the 58 kDa protein fraction was
significant (p , 0.001) as compared with that of the control.
SMase was immunohistochemically located in the spinous-
horny cells in the lesional skin of AD patients SMase was located
in a dotted pattern in the stratum granulosum and the innermost cell
layers of the stratum corneum of normal skin, but in lesional skin of
AD patients, SMase was located in the spinous-granular cells and the
whole stratum corneum, as determined by immunohistochemical
examination. Many strong reaction products were observed in a dotted
pattern in the stratum granulosum cells and the innermost cell layers
Figure 3. A 58 kDa epidermal protein-rich fraction is obtained by
immunoprecipitation. Thirty micrograms of SF was applied to lane 1, and
the supernatants after immunoprecipitation of 30 µg of SF and 15 µl of either
anti-SM Ab or preimmune serum were applied to lanes 2 and 3, respectively.
To lanes 4 and 5, 5.2 and 3.0 µg of solubilized immunoprecipitates were applied,
respectively. (A) Coomassie brilliant blue R staining, (B) immunoblotting. In
(A) and (B), the materials analyzed on the gels were as follows; lane 1, SF; lane
2, SF, anti-SM Ab, and PAS; lane 3, SF, preimmune serum, and PAS; lane 4,
acetic acid-soluble fraction from the pellet after incubation of SF, anti-SM Ab,
and PAS; lane 5, acetic acid-soluble fraction from the pellet after incubation of
SF, preimmune serum, and PAS. The 58 kDa protein was partially purified, as
shown in part (B), lane 4, indicated by an arrow.
Table I. The 58 kDa protein-rich fraction had
the SMase activitya
Sphingomyelinase activity of the
58 kDa protein-rich fractionb
No. (dpm per µg/per min)
1 7119.4
2 3026.3
3 6086.3
4 4246.2
5 6940.4
6 4948.7
7 4571.4
Mean 6 SEM 5276.9 6 567.9
aThe 58 kDa protein-rich fractions (n 5 7) were obtained from the pellets of the
incubation mixtures of SF, PAS, and either anti-SMase Ab or preimmune serum (control).
The pellets were solubilized in 50 mM acetate buffer, pH 4.7, containing 20 mM calcium
chloride and 0.1% Triton X-100, and tested for SMase activity. The partially purified,
58 kDa protein-rich fraction contained an activity that converted [N-methyl-14C]-
sphingomyelin to 12C-phosphorycholine.
bThe radioactivity produced by the 58 kDa protein-rich fraction obtained by
immunoprecipitation was counted and the background (produced by protein precipitated
with preimmune serum) was subtrated from each value.
of the stratum corneum of normal skin analyzed by the labeled
streptavidin biotin method using anti-SM Ab (Fig 4A). In contrast,
dotted reaction products at the periphery of the cells in the upper
stratum spinosum, the stratum granulosum, and the whole stratum
corneum (Fig 4B, indicated by an arrowhead), and diffuse, weakly
positive reaction products in the cytoplasm of the lower stratum
spinosum cells, were observed in the chronic dermatitis lesion (lichen-
ification) of AD (Fig 4B). No reaction products were observed in
normal skin with preimmune serum (Fig 4C).
SMase was detected in the intercellular domain of the granular-
corneocytes by immunoelectron-microscopic examination As
shown in Fig 5, most gold particles appeared to be concentrated in
the intercellular domains at the granular-corneocytes transition zone.
Several gold particles were seen in small vesicles that were the size of
the lamellar granules (LG), although they lacked the lamellar structure
(Fig 5, insertion). In intercorneocyte domains in the stratum corneum,
the gold particles seemed to be located on the outer surface of the
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Figure 4. The 58 kDa protein was detected immunohistochemically in
the stratum granulosum cells. Frozen sections of normal human epidermis
(A and C) or a chronic dermatitis lesion (lichenification) of an AD patient (B)
were reacted with either anti-SM Ab, diluted 1:2000 (A and B), or preimmune
rabbit serum, diluted 1:2000 (C), and visualized by the labeled streptavidin
biotin method. In (A), there were three to four lines of dots in the stratum
granulosum and the innermost cell layers of the stratum corneum in normal
epidermis. In contrast, in (B), there were many dots at the periphery of the
cells in the upper part of the stratum spinosum, stratum granulosum, and stratum
corneum, and weakly reacted product was seen in the cytoplasm of the lower
part of stratum spinosum cells. In (C), there was no positive reaction. b, basal
cell layer; s, stratum spinosum; g, stratum granulosum; c, stratum corneum.
Arrowheads indicate positive reaction products. Scale bars: 40 µm.
corneocyte plasma membrane, as well as on the intercellular material
that is indicated by the open arrowheads in Fig 5. These intercellular
gold particles were detected only in the innermost three cell layers of
the stratum corneum. In contrast, most gold particles appeared to be
concentrated in the intercellular domains from granular to upper
stratum corneum cells in the lesional skin of AD patients (Fig 6A, B).
The total amount of the 58 kDa protein was slightly increased
in the lesional skin of AD patients as measured by QIA The
total amount of the 58 kDa protein in the skin of the inner surface of
the upper arm was 2.8 6 0.19 µg per 7 mm2 in nonlesional skin (n 5
10) of AD patients and 2.7 6 0.22 µg per 7 mm2 in the normal
control skin (n 5 10), whereas the amount in the lesional skins of AD
patients was 3.5 6 0.3 µg per 7 mm2 (n 5 7) (Fig 7). The total
amount of the 58 kDa protein was slightly increased in the lesional
skin, and this difference was significant (nonpaired student’s t test).
DISCUSSION
The polyclonal antibody produced by immunization with a synthetic
polypeptide corresponding to a portion of the amino acid sequence
deduced from the cDNA of human acid SMase reacted with only a
single, 58 kDa, pI 5.8 epidermal protein extracted from suction blister
Figure 5. Gold particles in the intercellular domains by
immunoelectron-microscopy. Gold particles were seen in the small vesicles
in the stratum granulosum cells and in the intercellular domain of the innermost
three cell layers of the stratum corneum. Scale bar: 1 µm. Insertion: higher
magnification; gold particles were seen in the small vesicles, some of which
were fused with the cell membrane. The arrows indicate the boundary of the
cell, the arrowheads indicate the membrane of the small vesicles in the stratum
granulosum, and the open arrowheads indicate the intercellular materials. G,
keratohyalin granules; C, stratum corneum. Scale bar: 1 µm.
epidermis. If SM acylase carried the same epitope as that of the
antigenic synthetic polypeptide, there would have been two positively
reactive spots in the epidermal extract analyzed by two-dimensional
electrophoretic blotting; however, there was only a single spot. In
addition, this antibody cross-reacted with the 70 kDa human placental
SMase, as shown in Fig 1(B) (Sakuragawa, 1982). The 70 kDa placental
SMase may be a precursor protein, although the 54–57 kDa protein
was not detected in our study (Rousson et al, 1993). The molecular
weight of our epidermal SMase (58 kDa) corresponds well with that
of the smallest (57 kDa) of the fibroblast SMases (Hurwitz et al, 1994).
In addition, the antigenic material reacting with this polyclonal antibody
was located by immuno-electron microscopy in LG-like vesicles of
the stratum granulosum cells and in the intercellular space of the
stratum corneum. These LG-like vesicles lacked the lamellar structure
because osmium tetroxide fixation was omitted in the specimens used
for immunoelectron microscopy; however, there are no granules other
than LG that could have secreted their contents into the intercellular
space in the stratum granulosum. These characteristics of this antigenic
material resembled those of SMase in neonatal mouse and fetal rat
skins (Elias et al, 1979; Freinkel et al, 1985). Based on these findings
and its pI value, the 58 kDa epidermal protein is concluded to be the
human epidermal acid SMase.
The barrier defect in atopic skin may be caused by the decrease of
the amount of ceramides in the stratum corneum (Melnik et al, 1988;
Imokawa et al, 1991a), or the failure to secrete the contents of LG
into the intercellular domain and to form the intercellular multilamellar
lipid sheets (Fartasch et al, 1992). Similar electron microscopic findings
suggesting the failure to secrete the contents of LG were made in
the skin of glycosyl-phosphatidyl-inositol (GPI)-anchored proteins-
knockout mice (Tarutani et al, 1997) and type 1 harlequin ichthyosis
(Dale et al, 1990). In both, transepidermal water loss (TEWL) was
increased. Glycosyl-phosphatidyl-inositol-anchored proteins and cera-
mides in vertebrates are cotransported from the Golgi apparatus to the
apical plasma membrane (Mays et al, 1995). In addition, an increase of
TEWL was seen in the skins of the knockout mice of the epidermal
trans-glutaminase gene (Matsuki et al, 1998), in which the formation
of cornified envelopes was disturbed. The increase of TEWL seen in
both knockout mouse skins suggests that the binding of ceramides
with the cornified envelope may be the fundamental reaction in the
formation of the barrier, i.e., the formation of multilamellar lipid sheets
in the intercellular domain in the stratum corneum. Indeed, it has
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Figure 6. Gold particles in the spinous cells and in the stratum corneum
cells of AD patients. Gold particles were seen in the intercellular domain of
cornified cells from the innermost to the middle part of the stratum corneum
cell layers (A), and also in the cytoplasm and the intercellular domain of the
spinous cells (B) in the lesional skin of AD patients. Scale bar: 1 µm. Arrows
indicate desmosomes and arrowheads indicate melanosomes.
already been found that some intercellular lipids are bound to the
cornified envelope (Schwarzendruber et al, 1987).
The amount of epidermal SMase in lesional AD skin was found to
be increased in this study, although the amount of ceramides was
decreased and TEWL was increased. The fact that the (probably
increased) amount of ceramides produced by the increased amount of
SMase in AD lesional skins failed to cause decreased TEWL, may have
been due to the failure to form multilamellar structures in the
intercellular domain, as Fartasch et al (1992) suggested; at least, it has
been verified that SMase metabolized sphingomyelin to ceramides
in vitro in human skin (Menon et al, 1986). Alternatively, epidermal
SMase may play a role in paracrine or autocrine cell surface sphingomye-
lin hydrolysis, leading to ceramide-mediated apoptosis (Hannun and
Bel, 1989; Kolesnick, 1991), because an apoptotic DNA ladder has
been found in the stratum granulosum (McCall and Cohen, 1991).
As possible causes of the decrease in ceramide content in atopic skin
(nonlesional skin) of AD patients, both the suppression of synthesis of
ceramides (Holleran et al, 1992, 1993) and the enhancement of the
degradation of ceramides (Wertz and Downing, 1990a, b; Stewart and
Downing, 1995) have been suggested. Although the amount of the
precursor protein of the activator protein of β-glucocerebrosidase
(prosaposin) was decreased in atopic skin (Cui et al, 1997), the activities
of two enzymes related to either synthesis (β-glucocerebrosidase) or
degradation (ceramidase) were normal (Jin et al, 1994). Therefore,
β-glucocerebrosidase may not be involved in the decrease of ceramides
in AD skin. On the other hand, as the activity of sphingomyelin
Figure 7. The amount of the 58 kDa protein in the lesional skin of AD
was slightly increased. The nonlesional skin of the inner surface of the upper
arm of AD patients, normal skins, and the lesional skins of various parts of the
body of AD patients were punch-biopsied. The total amount of the 58 kDa
protein was slightly increased in the lesional skin of AD patients. The difference
is significant (p , 0.05, nonpaired student’s t test). 1, the normal control (n 5
10); 2, the nonlesional skins of AD patients (n 5 10); 3, the lesional skins of
AD patients (n 5 7, three foreheads, one cheek, two necks, and one breast).
Error bars: SE.
acylase (SM acylase) was markedly increased in the lesional skin of AD
(Murata et al, 1996), a considerable amount of sphingomyelin was
hydrolyzed to sphingosyl-phosphorylcholine and free fatty acids, but
not to ceramides and phosphorylcholine. The amount of SMase,
however, was also found to be elevated in the lesional skin of AD
patients in this study; therefore, the amount of ceramides might not
be decreased if sufficient sphingomyelin were available. There are two
reports describing decreases in the amount of ceramides in AD patients’
skin (Melnik et al, 1988; Imokawa et al, 1991a). Imokawa et al (1991a)
measured the amount of ceramides in around the outer one-fourth of
cell layers of the stratum corneum. They found that the total amount
of ceramides in lesional and nonlesional skin of AD patients was around
64% and 68% of the amount in the normal control, respectively. There
was no significant difference between the amount of ceramides in the
lesional and nonlesional skin. In contrast, SM hydrolysis was 27 and
seven times higher in the lesional and nonlesional AD skins, respectively,
than in the control, and most SM hydrolysis was attributable to SM
acylase (Murata et al, 1996). Moreover, the TEWL of the lesional skins
of AD patients was 10 or seven times greater than that of the normal
control or of the nonlesional AD skin, respectively (Abe et al, 1978;
Yamamura et al, 1990). Therefore, there is a discrepancy between the
amounts of ceramides and the activity of SM acylases, or between the
amounts of ceramides and the values of TEWL. These observations
indicate that the impaired barrier function in AD skins may not be
simply ascribed to the decrease in the amount of ceramides, but may
partly be due to the malformation of multilamellar lipid sheets.
As far as the activation of SM acylase is concerned, SM acylase may
be a lysosomal enzyme, and as there are an increased number of
lysosomes in chronic AD (Prose et al, 1965), the activity of SM acylase
may be remarkably high in the lesional skins of AD patients. On the
other hand various enzymes may be activated in the lesional epidermis
of AD skins; e.g., enzymes related to the synthetic pathways of
interleukin-8 or RANTES (Regulated on activation, normal T
expressed and secreted) may be activated, as the production of both
interleukin-8 and RANTES were specifically increased in the lesional
skin of AD patients (Zweiman et al, 1997). In addition, some protease
inhibitors, such as elafin and antileukoprotease, were produced only
in psoriatic lesional skins, but not in normal epidermis (Seemuller et al,
1986; Wiedow et al, 1990, 1993; Boudier and Bieth, 1992; Molhuizen
et al, 1993). Therefore, the activation of SM acylase may be the result
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of atopic inflammation, which is now understood to be different from
the allergic contact dermatitis.
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